IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC
Posted: Monday, September 20, 2021
The results of the phase II CheckMate 907 study appear to support the de novo administration of nivolumab, at 480 mg every 4 weeks, for the second-line treatment of advanced or metastatic non–small cell lung cancer (NSCLC). According to Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto, and colleagues, the study results are consistent with registrational studies that used weight-based nivolumab for second-line treatment of advanced NSCLC. The results were presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (Abstract FP04.01).
The research team evaluated the safety profile of de novo nivolumab among 129 patients with immunotherapy-naive advanced or metastatic NSCLC. Patients received 480 mg of nivolumab every 4 weeks. The minimum follow-up was 26.5 months.
The investigators identified no new safety signals. The most common select treatment-related adverse events of any grade included skin (34.1%), hepatic (20.2%), gastrointestinal (14%), and endocrine (10.1%) events. Grade 3 or 4 treatment-related adverse events occurred in 4.7% of patients; of those patients, 1.6% discontinued treatment as a result. No grade 5 treatment-related select adverse events were reported.
The median overall survival was 10.6 months, and the 1- and 2-year overall survival rates were 46.5% and 24.9%, respectively. The median progression-free survival rate was 3.7 months. The 1- and 2-year progression-free survival rates were 18.9% and 10.8%, respectively. The confirmed overall response rate was 17.1% (n = 22). Of the patients who responded, 63.3% (n = 14) remained in response until the minimum follow-up of 26.5 months.
Disclosure: For study authors’ disclosures, visit library.iaslc.org.
